Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2008-11-20

AUTHORS

Tanya B. Dorff, Denice Tsao-Wei, Gus Miranda, Donald G. Skinner, John P. Stein, David I. Quinn

ABSTRACT

ObjectivesTo describe the tolerability of two chemotherapy regimens, gemcitabine and cisplatin (GC) and methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for adjuvant treatment of patients with locally advanced urothelial cancer after radical cystectomy.MethodsThe USC Department of Urology bladder cancer database was searched for subjects who received adjuvant chemotherapy following cystectomy for transitional cell carcinoma with extravesical and/or lymph node involvement, yielding 187 cases. Clinical details regarding toxicity, number of cycles administered, and cancer outcome were analyzed.ResultsThe majority of subjects had lymph node involvement (70%). Sixty-eight percent of subjects received MVAC and 32% received GC, the latter regimen was predominant after 2000. Fifty-six percent of subjects received all four planned cycles (51% GC and 58% MVAC). With a median follow-up of 11.2 years (range 1.9–19.6), 96 patients (51%) have suffered a relapse, with no significant difference between chemotherapy regimens. Median time to recurrence for the population was 3.7 years and median overall survival is 4.6 years (3.0–9.3). The median time from recurrence to death was 6.7 months and was not significantly different between MVAC and GC.ConclusionsBoth MVAC and GC are tolerated after cystectomy for advanced urothelial carcinoma. A significant proportion of high-risk patients survive, free of disease, beyond 10 years. At recurrence, patients previously treated with adjuvant chemotherapy have a survival that appears much shorter than patients who develop metastases in the absence of this exposure, suggesting resistance to salvage chemotherapy. More... »

PAGES

39-44

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00345-008-0342-4

DOI

http://dx.doi.org/10.1007/s00345-008-0342-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1021499032

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/19020886


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "California", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Transitional Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxycytidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Doxorubicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Feasibility Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Methotrexate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Universities", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Urinary Bladder Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vinblastine", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "USC Norris Cancer Center, 1441 Eastlake Ave., Room 3440, 90033, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "USC Keck School of Medicine, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA", 
            "USC Norris Cancer Center, 1441 Eastlake Ave., Room 3440, 90033, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dorff", 
        "givenName": "Tanya B.", 
        "id": "sg:person.01007666002.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007666002.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "USC Norris Cancer Center, 1441 Eastlake Ave., Room 3440, 90033, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "USC Norris Cancer Center, 1441 Eastlake Ave., Room 3440, 90033, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tsao-Wei", 
        "givenName": "Denice", 
        "id": "sg:person.010304735667.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010304735667.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "USC Norris Cancer Center, 1441 Eastlake Ave., Room 3440, 90033, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "USC Norris Cancer Center, 1441 Eastlake Ave., Room 3440, 90033, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miranda", 
        "givenName": "Gus", 
        "id": "sg:person.0632606342.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632606342.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "USC Keck School of Medicine, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "USC Keck School of Medicine, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Skinner", 
        "givenName": "Donald G.", 
        "id": "sg:person.0770566644.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770566644.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "USC Keck School of Medicine, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "USC Keck School of Medicine, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stein", 
        "givenName": "John P.", 
        "id": "sg:person.0757510711.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0757510711.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "USC Keck School of Medicine, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "USC Keck School of Medicine, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Quinn", 
        "givenName": "David I.", 
        "id": "sg:person.01013134010.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013134010.15"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2008-11-20", 
    "datePublishedReg": "2008-11-20", 
    "description": "ObjectivesTo describe the tolerability of two chemotherapy regimens, gemcitabine and cisplatin (GC) and methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for adjuvant treatment of patients with locally advanced urothelial cancer after radical cystectomy.MethodsThe USC Department of Urology bladder cancer database was searched for subjects who received adjuvant chemotherapy following cystectomy for transitional cell carcinoma with extravesical and/or lymph node involvement, yielding 187 cases. Clinical details regarding toxicity, number of cycles administered, and cancer outcome were analyzed.ResultsThe majority of subjects had lymph node involvement (70%). Sixty-eight percent of subjects received MVAC and 32% received GC, the latter regimen was predominant after 2000. Fifty-six percent of subjects received all four planned cycles (51% GC and 58% MVAC). With a median follow-up of 11.2\u00a0years (range 1.9\u201319.6), 96 patients (51%) have suffered a relapse, with no significant difference between chemotherapy regimens. Median time to recurrence for the population was 3.7\u00a0years and median overall survival is 4.6\u00a0years (3.0\u20139.3). The median time from recurrence to death was 6.7\u00a0months and was not significantly different between MVAC and GC.ConclusionsBoth MVAC and GC are tolerated after cystectomy for advanced urothelial carcinoma. A significant proportion of high-risk patients survive, free of disease, beyond 10\u00a0years. At recurrence, patients previously treated with adjuvant chemotherapy have a survival that appears much shorter than patients who develop metastases in the absence of this exposure, suggesting resistance to salvage chemotherapy.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00345-008-0342-4", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094127", 
        "issn": [
          "0724-4983", 
          "1433-8726"
        ], 
        "name": "World Journal of Urology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "27"
      }
    ], 
    "keywords": [
      "advanced urothelial carcinoma", 
      "lymph node involvement", 
      "percent of subjects", 
      "adjuvant chemotherapy", 
      "node involvement", 
      "median time", 
      "urothelial carcinoma", 
      "advanced urothelial cancer", 
      "median overall survival", 
      "high-risk patients", 
      "bladder cancer database", 
      "transitional cell carcinoma", 
      "majority of subjects", 
      "chemotherapy regimens", 
      "adjuvant treatment", 
      "overall survival", 
      "radical cystectomy", 
      "urothelial cancer", 
      "latter regimen", 
      "cell carcinoma", 
      "cancer outcomes", 
      "clinical details", 
      "Cancer Database", 
      "chemotherapy", 
      "patients", 
      "USC Experience", 
      "cystectomy", 
      "carcinoma", 
      "MVAC", 
      "significant differences", 
      "recurrence", 
      "significant proportion", 
      "cisplatin", 
      "subjects", 
      "survival", 
      "years", 
      "involvement", 
      "tolerability", 
      "percent", 
      "regimens", 
      "regimen", 
      "gemcitabine", 
      "relapse", 
      "metastasis", 
      "cancer", 
      "ObjectivesTo", 
      "disease", 
      "months", 
      "death", 
      "vinblastine", 
      "outcomes", 
      "doxorubicin", 
      "treatment", 
      "toxicity", 
      "exposure", 
      "Department", 
      "majority", 
      "population", 
      "proportion", 
      "GC", 
      "differences", 
      "absence", 
      "database", 
      "cases", 
      "time", 
      "resistance", 
      "experience", 
      "cycle", 
      "number", 
      "overview", 
      "number of cycles", 
      "detail"
    ], 
    "name": "Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience", 
    "pagination": "39-44", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1021499032"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00345-008-0342-4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "19020886"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00345-008-0342-4", 
      "https://app.dimensions.ai/details/publication/pub.1021499032"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T20:53", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_466.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00345-008-0342-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00345-008-0342-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00345-008-0342-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00345-008-0342-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00345-008-0342-4'


 

This table displays all metadata directly associated to this object as RDF triples.

254 TRIPLES      20 PREDICATES      118 URIs      110 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00345-008-0342-4 schema:about N0bc617b18daa420b824560b9d2c86ae0
2 N0e38eabf22214e6bab86abcf41f48ebe
3 N23ea690411ed440eb64808cea737c81a
4 N2fb713f91df1484c884b7323d45d5a6f
5 N39c8c5db7321499bbc3c5f7cc8b3cf99
6 N48a55e53309642d3b3fadfd77ae9a7b5
7 N5e8fd5b8a14949a0b38970ba5ae38684
8 N600c7495820449c7b92b8993ce00a861
9 N618b6c6106134b0bb427f525fbbcf64f
10 N61d703a0c59644069a2339fd57ee7f39
11 N6cdfd9eef91b41a1893e2b982b244b03
12 N6ce53aae76f34a6a847664e9c19e9a80
13 N813f91bfba6a4432ae54f47bd2dbf792
14 N8782646676ec4732bc22671aeed56626
15 N8d8351ed75d144288129af21b1196707
16 N9761da028c554a9dadb92ab156f48456
17 N9944c3f62ad14faabb967c8806135f71
18 N9e86429c401a4639a2fe1fdb0b803629
19 Nb48cf8ca2fad4eeeb8b72f51d1adca17
20 Ne8e16cb6063b4459ac85f477063e0fee
21 Nf4342f4fb0d742eab1123c4077183c14
22 anzsrc-for:11
23 anzsrc-for:1112
24 schema:author N49930198592e4719a20d70427f41001e
25 schema:datePublished 2008-11-20
26 schema:datePublishedReg 2008-11-20
27 schema:description ObjectivesTo describe the tolerability of two chemotherapy regimens, gemcitabine and cisplatin (GC) and methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for adjuvant treatment of patients with locally advanced urothelial cancer after radical cystectomy.MethodsThe USC Department of Urology bladder cancer database was searched for subjects who received adjuvant chemotherapy following cystectomy for transitional cell carcinoma with extravesical and/or lymph node involvement, yielding 187 cases. Clinical details regarding toxicity, number of cycles administered, and cancer outcome were analyzed.ResultsThe majority of subjects had lymph node involvement (70%). Sixty-eight percent of subjects received MVAC and 32% received GC, the latter regimen was predominant after 2000. Fifty-six percent of subjects received all four planned cycles (51% GC and 58% MVAC). With a median follow-up of 11.2 years (range 1.9–19.6), 96 patients (51%) have suffered a relapse, with no significant difference between chemotherapy regimens. Median time to recurrence for the population was 3.7 years and median overall survival is 4.6 years (3.0–9.3). The median time from recurrence to death was 6.7 months and was not significantly different between MVAC and GC.ConclusionsBoth MVAC and GC are tolerated after cystectomy for advanced urothelial carcinoma. A significant proportion of high-risk patients survive, free of disease, beyond 10 years. At recurrence, patients previously treated with adjuvant chemotherapy have a survival that appears much shorter than patients who develop metastases in the absence of this exposure, suggesting resistance to salvage chemotherapy.
28 schema:genre article
29 schema:isAccessibleForFree false
30 schema:isPartOf Nb56a98df3b3f432eac4d94a691d656b3
31 Ne94214a9825a424ab908c3d87f805c3e
32 sg:journal.1094127
33 schema:keywords Cancer Database
34 Department
35 GC
36 MVAC
37 ObjectivesTo
38 USC Experience
39 absence
40 adjuvant chemotherapy
41 adjuvant treatment
42 advanced urothelial cancer
43 advanced urothelial carcinoma
44 bladder cancer database
45 cancer
46 cancer outcomes
47 carcinoma
48 cases
49 cell carcinoma
50 chemotherapy
51 chemotherapy regimens
52 cisplatin
53 clinical details
54 cycle
55 cystectomy
56 database
57 death
58 detail
59 differences
60 disease
61 doxorubicin
62 experience
63 exposure
64 gemcitabine
65 high-risk patients
66 involvement
67 latter regimen
68 lymph node involvement
69 majority
70 majority of subjects
71 median overall survival
72 median time
73 metastasis
74 months
75 node involvement
76 number
77 number of cycles
78 outcomes
79 overall survival
80 overview
81 patients
82 percent
83 percent of subjects
84 population
85 proportion
86 radical cystectomy
87 recurrence
88 regimen
89 regimens
90 relapse
91 resistance
92 significant differences
93 significant proportion
94 subjects
95 survival
96 time
97 tolerability
98 toxicity
99 transitional cell carcinoma
100 treatment
101 urothelial cancer
102 urothelial carcinoma
103 vinblastine
104 years
105 schema:name Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience
106 schema:pagination 39-44
107 schema:productId N0ccd009b1f4a4599972e85508780990d
108 N49c7f85af1404a6289da52eb23b6a61f
109 Nc010a76b9600485d8d2b8eb2997f447a
110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021499032
111 https://doi.org/10.1007/s00345-008-0342-4
112 schema:sdDatePublished 2022-11-24T20:53
113 schema:sdLicense https://scigraph.springernature.com/explorer/license/
114 schema:sdPublisher N38c1b72993d44024bf904d378f2a8abe
115 schema:url https://doi.org/10.1007/s00345-008-0342-4
116 sgo:license sg:explorer/license/
117 sgo:sdDataset articles
118 rdf:type schema:ScholarlyArticle
119 N0bc617b18daa420b824560b9d2c86ae0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Humans
121 rdf:type schema:DefinedTerm
122 N0ccd009b1f4a4599972e85508780990d schema:name pubmed_id
123 schema:value 19020886
124 rdf:type schema:PropertyValue
125 N0e38eabf22214e6bab86abcf41f48ebe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Universities
127 rdf:type schema:DefinedTerm
128 N23ea690411ed440eb64808cea737c81a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Feasibility Studies
130 rdf:type schema:DefinedTerm
131 N2fb713f91df1484c884b7323d45d5a6f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Aged
133 rdf:type schema:DefinedTerm
134 N356008d0e3c142228c0c266cfae92dd3 rdf:first sg:person.0757510711.79
135 rdf:rest Nf5563b4933364618b45960ca7a3ebab1
136 N388b23cc60c5444c93daf9c05b3249cb rdf:first sg:person.010304735667.62
137 rdf:rest Nb05db73e44ca4516a7a4bd8ee7c74477
138 N38c1b72993d44024bf904d378f2a8abe schema:name Springer Nature - SN SciGraph project
139 rdf:type schema:Organization
140 N39c8c5db7321499bbc3c5f7cc8b3cf99 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Cisplatin
142 rdf:type schema:DefinedTerm
143 N48a55e53309642d3b3fadfd77ae9a7b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Carcinoma, Transitional Cell
145 rdf:type schema:DefinedTerm
146 N49930198592e4719a20d70427f41001e rdf:first sg:person.01007666002.23
147 rdf:rest N388b23cc60c5444c93daf9c05b3249cb
148 N49c7f85af1404a6289da52eb23b6a61f schema:name doi
149 schema:value 10.1007/s00345-008-0342-4
150 rdf:type schema:PropertyValue
151 N5e8fd5b8a14949a0b38970ba5ae38684 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Male
153 rdf:type schema:DefinedTerm
154 N600c7495820449c7b92b8993ce00a861 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Middle Aged
156 rdf:type schema:DefinedTerm
157 N618b6c6106134b0bb427f525fbbcf64f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Deoxycytidine
159 rdf:type schema:DefinedTerm
160 N61d703a0c59644069a2339fd57ee7f39 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Female
162 rdf:type schema:DefinedTerm
163 N6cdfd9eef91b41a1893e2b982b244b03 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Aged, 80 and over
165 rdf:type schema:DefinedTerm
166 N6ce53aae76f34a6a847664e9c19e9a80 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Urinary Bladder Neoplasms
168 rdf:type schema:DefinedTerm
169 N813f91bfba6a4432ae54f47bd2dbf792 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Disease Progression
171 rdf:type schema:DefinedTerm
172 N8782646676ec4732bc22671aeed56626 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Chemotherapy, Adjuvant
174 rdf:type schema:DefinedTerm
175 N8d8351ed75d144288129af21b1196707 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name California
177 rdf:type schema:DefinedTerm
178 N9761da028c554a9dadb92ab156f48456 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Vinblastine
180 rdf:type schema:DefinedTerm
181 N9944c3f62ad14faabb967c8806135f71 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Doxorubicin
183 rdf:type schema:DefinedTerm
184 N9e86429c401a4639a2fe1fdb0b803629 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Retrospective Studies
186 rdf:type schema:DefinedTerm
187 Na5326bb71e9e41b1b90a67d8e078bc8e rdf:first sg:person.0770566644.20
188 rdf:rest N356008d0e3c142228c0c266cfae92dd3
189 Nb05db73e44ca4516a7a4bd8ee7c74477 rdf:first sg:person.0632606342.26
190 rdf:rest Na5326bb71e9e41b1b90a67d8e078bc8e
191 Nb48cf8ca2fad4eeeb8b72f51d1adca17 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Antineoplastic Combined Chemotherapy Protocols
193 rdf:type schema:DefinedTerm
194 Nb56a98df3b3f432eac4d94a691d656b3 schema:volumeNumber 27
195 rdf:type schema:PublicationVolume
196 Nc010a76b9600485d8d2b8eb2997f447a schema:name dimensions_id
197 schema:value pub.1021499032
198 rdf:type schema:PropertyValue
199 Ne8e16cb6063b4459ac85f477063e0fee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Methotrexate
201 rdf:type schema:DefinedTerm
202 Ne94214a9825a424ab908c3d87f805c3e schema:issueNumber 1
203 rdf:type schema:PublicationIssue
204 Nf4342f4fb0d742eab1123c4077183c14 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Adult
206 rdf:type schema:DefinedTerm
207 Nf5563b4933364618b45960ca7a3ebab1 rdf:first sg:person.01013134010.15
208 rdf:rest rdf:nil
209 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
210 schema:name Medical and Health Sciences
211 rdf:type schema:DefinedTerm
212 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
213 schema:name Oncology and Carcinogenesis
214 rdf:type schema:DefinedTerm
215 sg:journal.1094127 schema:issn 0724-4983
216 1433-8726
217 schema:name World Journal of Urology
218 schema:publisher Springer Nature
219 rdf:type schema:Periodical
220 sg:person.01007666002.23 schema:affiliation grid-institutes:grid.42505.36
221 schema:familyName Dorff
222 schema:givenName Tanya B.
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007666002.23
224 rdf:type schema:Person
225 sg:person.01013134010.15 schema:affiliation grid-institutes:grid.42505.36
226 schema:familyName Quinn
227 schema:givenName David I.
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013134010.15
229 rdf:type schema:Person
230 sg:person.010304735667.62 schema:affiliation grid-institutes:grid.42505.36
231 schema:familyName Tsao-Wei
232 schema:givenName Denice
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010304735667.62
234 rdf:type schema:Person
235 sg:person.0632606342.26 schema:affiliation grid-institutes:grid.42505.36
236 schema:familyName Miranda
237 schema:givenName Gus
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632606342.26
239 rdf:type schema:Person
240 sg:person.0757510711.79 schema:affiliation grid-institutes:grid.42505.36
241 schema:familyName Stein
242 schema:givenName John P.
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0757510711.79
244 rdf:type schema:Person
245 sg:person.0770566644.20 schema:affiliation grid-institutes:grid.42505.36
246 schema:familyName Skinner
247 schema:givenName Donald G.
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770566644.20
249 rdf:type schema:Person
250 grid-institutes:grid.42505.36 schema:alternateName USC Keck School of Medicine, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA
251 USC Norris Cancer Center, 1441 Eastlake Ave., Room 3440, 90033, Los Angeles, CA, USA
252 schema:name USC Keck School of Medicine, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA
253 USC Norris Cancer Center, 1441 Eastlake Ave., Room 3440, 90033, Los Angeles, CA, USA
254 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...